Surrogate Markers of Resectability in Patients Undergoing Exploration of Potentially Resectable Pancreatic Adenocarcinoma
- 28 November 2007
- journal article
- research article
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 12 (6) , 1068-1073
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Impact of Lymph Node Involvement on Long-term Survival after R0 Pancreaticoduodenectomy for Ductal Adenocarcinoma of the PancreasJournal of Gastrointestinal Surgery, 2007
- Post-operative neutrophil–lymphocyte ratio predicts complications following colorectal surgeryInternational Journal of Surgery, 2007
- Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: An international multicenter studySurgical Endoscopy, 2006
- Patient with Markedly Elevated CA 19-9 Not Associated with MalignancySouthern Medical Journal, 2006
- Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancerSurgical Oncology, 2005
- Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreasThe American Journal of Surgery, 2005
- Preoperative Staging and Tumor Resectability Assessment of Pancreatic Cancer: Prospective Study Comparing Endoscopic Ultrasonography, Helical Computed Tomography, Magnetic Resonance Imaging, and AngiographyAmerican Journal of Gastroenterology, 2004
- Pancreatic cancerThe Lancet, 2004
- Inflammation and cancerNature, 2002
- Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundiceEuropean Journal of Surgical Oncology, 2000